<?xml version="1.0" encoding="UTF-8"?>
<p id="para370">Serious adverse events occurred in 20 (1%) participants: eight in the clinic group, five in the hybrid group, and seven in the community group (all 1%; 
 <xref rid="sec1" ref-type="sec">appendix p 10</xref>); 14 (70%) of 20 of the serious adverse events (seven in the clinic group, one in the hybrid group, and six in the community group) were considered related or possibly related to HIV. Excluding serious adverse events, 13 (1%) participants had a severe adverse event (all grade 3) in the study: two in the clinic group, four in the hybrid group, and seven in the community group, of which nine were due to high blood pressure, which was measured routinely in the community groups and once in the clinic group. Excluding the high blood pressure readings, of the four participants with other severe adverse events, one occurred in the clinic group, two in the hybrid group, and one in the community-based group. Reported social harms related to trial participation occurred in two participants; both participants were in the community-based group.
</p>
